zuranolone
Selected indexed studies
- Zuranolone for the Treatment of Postpartum Depression. (Am J Psychiatry, 2023) [PMID:37491938]
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. (JAMA Psychiatry, 2021) [PMID:34190962]
- Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA(A) receptors. (Pharmacol Biochem Behav, 2024) [PMID:38387651]
_Worker-drafted node — pending editorial review._
Connections
zuranolone is a side effect of
Sources
- Zuranolone for the Treatment of Postpartum Depression. (2023) pubmed
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. (2021) pubmed
- Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA(A) receptors. (2024) pubmed
- Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies. (2024) pubmed
- Zuranolone. (2006) pubmed
- Zuranolone: First Approval. (2023) pubmed
- Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial. (2023) pubmed
- Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. (2020) pubmed
- Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression. (2024) pubmed
- Zuranolone for the Treatment of Postpartum Depression. (2025) pubmed